Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

622 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early therapeutic intervention with methotrexate prevents the development of rheumatoid arthritis in patients with recent-onset undifferentiated arthritis: A prospective cohort study.
Kudo-Tanaka E, Shimizu T, Nii T, Teshigawara S, Yoshimura M, Watanabe A, Tsuji S, Tsuboi H, Hirao M, Yura A, Harada Y, Sueishi M, Suenaga Y, Chiba N, Tonai T, Saisho K, Ogata A, Matsushita M, Hashimoto J, Ohshima S, Tohma S, Saeki Y. Kudo-Tanaka E, et al. Among authors: ogata a. Mod Rheumatol. 2015;25(6):831-6. doi: 10.3109/14397595.2015.1031364. Epub 2015 Apr 30. Mod Rheumatol. 2015. PMID: 25800638
Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.
Ogata A, Tanimura K, Sugimoto T, Inoue H, Urata Y, Matsubara T, Kondo M, Ueki Y, Iwahashi M, Tohma S, Ohta S, Saeki Y, Tanaka T; Musashi Study Investigators. Ogata A, et al. Arthritis Care Res (Hoboken). 2014 Mar;66(3):344-54. doi: 10.1002/acr.22110. Arthritis Care Res (Hoboken). 2014. PMID: 23983039 Free PMC article. Clinical Trial.
Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic Implications.
Yoshida Y, Ogata A, Kang S, Ebina K, Shi K, Nojima S, Kimura T, Ito D, Morimoto K, Nishide M, Hosokawa T, Hirano T, Shima Y, Narazaki M, Tsuboi H, Saeki Y, Tomita T, Tanaka T, Kumanogoh A. Yoshida Y, et al. Among authors: ogata a. Arthritis Rheumatol. 2015 Jun;67(6):1481-90. doi: 10.1002/art.39086. Arthritis Rheumatol. 2015. PMID: 25707877 Free PMC article.
Increased levels of plasma nucleotides in patients with rheumatoid arthritis.
Kishikawa T, Maeda Y, Nii T, Arase N, Hirata J, Suzuki K, Yamamoto K, Masuda T, Ogawa K, Tsuji S, Matsushita M, Matsuoka H, Yoshimura M, Tsunoda S, Ohshima S, Narazaki M, Ogata A, Saeki Y, Inohara H, Kumanogoh A, Takeda K, Okada Y. Kishikawa T, et al. Among authors: ogata a. Int Immunol. 2021 Jan 28;33(2):119-124. doi: 10.1093/intimm/dxaa059. Int Immunol. 2021. PMID: 32866240 Free PMC article.
Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population.
Kishikawa T, Maeda Y, Nii T, Motooka D, Matsumoto Y, Matsushita M, Matsuoka H, Yoshimura M, Kawada S, Teshigawara S, Oguro E, Okita Y, Kawamoto K, Higa S, Hirano T, Narazaki M, Ogata A, Saeki Y, Nakamura S, Inohara H, Kumanogoh A, Takeda K, Okada Y. Kishikawa T, et al. Among authors: ogata a. Ann Rheum Dis. 2020 Jan;79(1):103-111. doi: 10.1136/annrheumdis-2019-215743. Epub 2019 Nov 7. Ann Rheum Dis. 2020. PMID: 31699813 Free PMC article.
A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
Ogata A, Tanaka Y, Ishii T, Kaneko M, Miwa H, Ohsawa S; SHINOBI study group. Ogata A, et al. Mod Rheumatol. 2018 Jan;28(1):76-84. doi: 10.1080/14397595.2017.1332507. Epub 2017 Jun 16. Mod Rheumatol. 2018. PMID: 28622048 Clinical Trial.
Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients.
Watanabe K, Sakai R, Koike R, Sakai F, Sugiyama H, Tanaka M, Komano Y, Akiyama Y, Mimura T, Kaneko M, Tokuda H, Iso T, Motegi M, Ikeda K, Nakajima H, Taki H, Kubota T, Kodama H, Sugii S, Kuroiwa T, Nawata Y, Shiozawa K, Ogata A, Sawada S, Matsukawa Y, Okazaki T, Mukai M, Iwahashi M, Saito K, Tanaka Y, Nanki T, Miyasaka N, Harigai M. Watanabe K, et al. Among authors: ogata a. Mod Rheumatol. 2013 Nov;23(6):1085-93. doi: 10.1007/s10165-012-0796-5. Epub 2012 Dec 5. Mod Rheumatol. 2013. PMID: 23212592
Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
Ogata A, Tanaka Y, Ishii T, Kaneko M, Miwa H, Ohsawa S, Yamakawa R; SHINOBI Study Group. Ogata A, et al. Mod Rheumatol. 2019 Sep;29(5):767-774. doi: 10.1080/14397595.2018.1533514. Epub 2018 Dec 14. Mod Rheumatol. 2019. PMID: 30299202 Clinical Trial.
622 results